Methionine aminopeptidase 2 inhibition: Antiangiogenesis and tumour therapy

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 1, 2004, Pages 1-6

  Bradshaw, Ralph A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Antisense inhibition; Cell cycle; Dominant negative inhibition; Endothelial cells; Fumagillin; Methionine aminopeptidase (MetAP); Neovascularisation; Oncology; Ovalicin; Tumour therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CKD 731; ENZYME INHIBITOR; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; METHIONINE; METHIONYL AMINOPEPTIDASE; METHIONYL AMINOPEPTIDASE 2; OVALICIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CATALYSIS; CELL CYCLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; EDITORIAL; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HYDROLYSIS; MITOSIS INHIBITION; NEUROTOXICITY; PATENT; PROTEIN SYNTHESIS; STRUCTURE ACTIVITY RELATION;

EID: 0346656640     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.1.1     Document Type: Editorial

References (39)

1. BRADSHAW RA, HOPE CJ, YI E, WALKER KW: Co- and post-translational processing; the removal of methionine. In The Enzymes: Co- and Post-translational Proteolysis of Proteins. Dalbey RE et al. (Eds) Academic press, San Diego, USA (2001):389-420.
2. ARFIN SM, KENDALL RL, HALL L et al.: Eukaryotic methionyl aminopeptidases: two classes of cobalt-dependent enzymes. Proc. Natl Acad. Sci. USA (1995) 92:7714-7718.
3. BRADSHAW RA, BRICKEY WW, WALKER KW: N-terminal processing: the methionine aminopeptidase and N-α-acetyl transferase families. Trends Biochem. Sci (1998) 23:263-267.
4. TOWLER DA, EUBANKS SR, TOWERY DS, ADAMS SP, GLASER L: Amino-terminal processing of proteins by N-myristoylation. Substrate specificity of N-myristoyl transferase. J. Biol. Chem. (1987) 262:1030-1036.
5. GIGLIONE C, SERERO A, PIERRE M, BOISSON B, MEINNEL T: Identification of eukaryotic peptide deformylases reveals universality of N-terminal protein processing mechanisms. EMBO J. (2000) 21:5916-5929.
6. LIU S, WIDOM J, KEMP CW, CREWS CM, CLARDY J: Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science (1998) 282:1324-1327.
7. RODERICK SL, MATTHEWS BW: Structure of the cobalt-dependent methionine aminopeptidase from Escherichia coli: a new type of proteolytic enzyme. Biochemistry (1993) 32:3907-3912.
8. MILLER CG, STRAUCH KL, KUKRAL AM et al.: N-terminal methionine-specific peptidase in Salmonella typhimurium. Proc. Natl Acad. Sci. USA (1987) 84:2718-2722.
9. BEN-BASSAT A, BAUER K, CHANG SY et al.: Processing of the initiation methionine from proteins: properties of the Escherichia coli methionine aminopeptidase and its gene structure. J. Bacteriol. (1987) 169:751-757.
10. D'SOUZA VM, HOLZ RC: The methionyl aminopeptidase from Escherichia coli can function as an iron (II) enzyme. Biochemistry (1999) 38:11079-11085.
11. D'SOUZA VM, BENNETT B, COPIK AJ, HOLZ RC: Divalent metal binding properties of the methionyl aminopeptidase from Escherichia coli. Biochemistry (2000) 39:3817-3826.
12. D'SOUZA VM, SWIERCZEK SI, COSPER NJ et al.: Kinetic and structural characterization of manganese(II)-loaded methionyl aminopeptidases. Biochemistry (2002) 41:13096-13105.
13. MENG L, RUEBUSH S, D'SOUZA VM et al.: Overexpression and divalent metal binding properties of the methionyl aminopeptidase from Pyrococcus furiosus. Biochemistry (2002) 41:7199-7108.
14. WANG J, SHEPPARD GS, LOU P et al.: Physiologically relevant metal cofactor for methionine aminopeptidase-2 is manganese. Biochemistry (2003) 42:5035-5042.
15. 2+ as a cofactor: a case of mistaken identity? Protein Sci. (1998) 7:2684-2687.
16. LI X, CHANG YH: Amino-terminal protein processing in Saccharomyces cerevisiae is an essential function that requires two distinct methionine aminopeptidases. Proc. Natl Acad. Sci. USA (1995) 92:12357-12361.
17. CHANG SY, MCGARY EC, CHANG S: Methionine aminopeptidase gene of Escherichia coli is essential for cell growth. J. Bacteriol. (1989) 171:4071-4072.
18. TURK BE, GRIFFITH EC, WOLF S et al.: Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells. Chem. Biol. (1999) 6:823-833.
19. SIN N, MENG L, WANG MQ et al.: The antiangiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. Natl Acad. Sci. US4 (1997) 94:2362-2367.
20. GRIFFITH EC, SU Z, TURK BE et al.: Methionine aminopeptidase (Type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem. Biol. (1997) 4:461-471.
21. MCCOWEN M, CALLENDER M, LAWLIS J: Fumagillin (H-3), a new antibiotic with amebicidal properties. Science (1951) 113:202-203.
22. SIGG HP, WEBER HP: Isolation and structure elucidation of ovalicin. Helv. Chim. Acta. (1968) 51:1395-1408.
23. HARTMANN GR, RICHTER H, WEINER EM, ZIMMERMANN W: On the mechanism of action of the cytostatic drug anguidine and of the immunosuppressive agent ovalicin, two sesquiterpenes from fungi. Planta Med. (1978) 34:231-252.
24. GRIFFITH EC, SU Z, NIWAYAMA S et al.: Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. Proc. Natl Acad. Sci. USA (1998) 95:15183-15188.
25. LOWTHER WT, MCMILLEN DA, ORVILLE AM, MATTHEWS BW: The antiangiogenic agent fumagillin covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase. Proc. Natl Acad. Sci. USA (1998) 95:12153-12157.
26. HAN C, AHN S, CHOI N et al.: Design and synthesis of highly potent fumagillin analogues from homology modeling for a human MetAP-2. Bioorg. Med. Chem. Lett. (2000) 10:39-43.
27. LUO QL, LI JY, LIU ZY et al.: Discovery and structural modification of inhibitors of methionine aminopeptidases from Escherichia coli and Saccharomyces cerevisiae. J. Med. Chem. (2003) 46:2631-2640.
28. KEDING S, DALES N, LIM S, BEAULIEU D, RICH D: Synthesis of (3R)-amino-(2S)-hydroxy amino acids for the inhibition of methionine aminopeptidase-1. Synthesis Commun. (1998) 28:4463-4470.
29. INGBER D, FUJITA T, KISHIMOTO S et al.: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature (1990) 348:555-557.
30. CASTRONOVO V, BELOTTI D: TNP-470 (AGM-1470): mechanisms of action and early clinical development. Eur. J. Cancer (1996) 32A:2520-2527.
31. KUSAKA M, SUDO Y, MATSUTANI E et al.: Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br. J. Cancer (1994) 69:212-216.
32. ABE J, ZHOU W, TAKUWA N et al.: A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res. (1994) 54:3407-3412.
33. HORI A, IKEYAMA S, SUDO K: Suppression of cyclin D1 mRNA expression by the angiogenesis inhibitor TNP-470 (AGM-1470) in vascular endothelial cells. Biochem. Biophys. Res. Commun. (1994) 204:1067-1073.
34. YEH J, MOHAN R, CREWS C: The antiangiogenic agent TNP-470 requires p53 and p21 CIP/WAF for endothelial cell growth arrest. Proc. Natl Acad. Sci. USA (2000) 23:12782-12787.
35. ZHANG Y, GRIFFITH EC, SAGE J, JACKS T, LIU JO: Cell cycle inhibition by the antiangiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc. Natl Acad. Sci. USA (2000) 97:6427-6432.
36. MASIERO L, FIGG WD, KOHN EC: New antiangiogenesis agents: review of the clinical experience with carboxyamidotriazole (CAI), thalidomide, TNP-470 and interleukin-12. Angiogenesis (1997) 1:23-35.
37. KRUGER EA, FIGG WD: TNP-470: an angiogenesis inhibitor in clinical development for cancer. Expert Opin. Investig. Drugs (2000) 9:1383-1396.
38. GIMBRONE M, LEAPMANS S, COTRANS R, FOLKMAN J: Tumor dormancy in vitro by prevention of neovascularization. J. Exp. Med. (1972) 136:261-276.
39. KENDALL RL, BRADSHAW RA: Isolation and characterization of the methionine aminopeptidase from porcine liver responsible for the co-translational prcessing of proteins. J. Biol. Chem. (1992) 267:20667-20673.